Application of monoclonal antibodies for the identification of the antigenic site for poliovirus neutralization.
Antigenic mutants of type 3 poliovirus were obtained by picking plaques formed in the presence of neutralizing monoclonal antibodies. All the mutants were clustered into a single operationally defined antigenic site based on their reactions with a panel of antibodies. Most of the mutations were shown to be located in the virion protein VP1 by SDS-PAGE and oligonucleotide mapping and fifteen of sixteen mutants had single point mutations in a region of VP1 encompassing only eight amino acids, suggesting that this is a major target for the neutralization of the virus. While other areas may also be required, it is likely that this region is a necessary component of a vaccine of any kind.
D000911:Antibodies, Monoclonal / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology*; D000939:Epitopes / Q000276:immunology; D009154:Mutation; D009500:Neutralization Tests; D017955:Poliovirus / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology; D015678:Viral Structural Proteins
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000956:Antigens, Viral; D000939:Epitopes; D014764:Viral Proteins; D015678:Viral Structural Proteins